Nyxoah SA (NASDAQ:NYXH) Sees Significant Decrease in Short Interest

Nyxoah SA (NASDAQ:NYXH) saw a large decrease in short interest in the month of August. As of August 31st, there was short interest totaling 244,313 shares, a decrease of 48.5% from the August 15th total of 474,703 shares. Approximately 0.8% of the shares of the stock are sold short. Based on an average daily volume of 108,052 shares, the days-to-cover ratio is presently 2.3 days.

Nyxoah Trading Down 3.8%

Shares of NYXH traded down $0.06 during mid-day trading on Tuesday, hitting $1.54. 64,298 shares of the company were exchanged, compared to its average volume of 550,327. Nyxoah has a 1-year low of $1.26 and a 1-year high of $6.87. The company has a 50 day moving average of $1.56 and a 200-day moving average of $2.37. The company has a quick ratio of 2.31, a current ratio of 2.38 and a debt-to-equity ratio of 0.44.

Nyxoah (NASDAQ:NYXH) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.47) by ($0.20). Nyxoah had a negative return on equity of 178.90% and a negative net margin of 443.16%.The firm had revenue of $8.76 million during the quarter, compared to analyst estimates of $8.64 million. Equities analysts forecast that Nyxoah will post -1.45 EPS for the current year.

Institutional Trading of Nyxoah

Institutional investors have recently made changes to their positions in the company. Readystate Asset Management LP acquired a new stake in shares of Nyxoah in the second quarter worth approximately $351,000. IFP Advisors Inc raised its stake in Nyxoah by 35.6% in the 2nd quarter. IFP Advisors Inc now owns 118,426 shares of the company’s stock valued at $200,000 after purchasing an additional 31,061 shares during the last quarter. Finally, Integrated Wealth Concepts LLC purchased a new position in Nyxoah in the 2nd quarter valued at $169,000.

Analysts Set New Price Targets

Several analysts have commented on NYXH shares. Stifel Nicolaus dropped their price objective on Nyxoah from $5.00 to $3.00 and set a “hold” rating on the stock in a report on Wednesday, June 17th. Robert W. Baird set a $2.31 target price on Nyxoah in a research note on Thursday, August 6th. Wall Street Zen lowered Nyxoah from a “hold” rating to a “sell” rating in a research report on Sunday, August 9th. Cantor Fitzgerald reissued an “overweight” rating on shares of Nyxoah in a research note on Tuesday. Finally, Oppenheimer set a $4.00 price target on shares of Nyxoah in a report on Thursday, August 6th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $4.26.

Nyxoah Company Profile

Nyxoah SA, headquartered in Mont-Saint-Guibert, Belgium, is a medical technology company focused on neuromodulation therapies for sleep‐disordered breathing. Established in 2018, the company’s primary offering is the Genio® system, a minimally invasive bilateral hypoglossal nerve stimulator designed to treat moderate to severe obstructive sleep apnea (OSA). By electrically stimulating the genioglossus muscle, the device helps maintain airway patency during sleep, reducing apnea events and improving overall sleep quality.

The Genio system comprises a small, implantable stimulator positioned submentally and an external activation unit worn by the patient.